Jianling Yang

755 total citations · 1 hit paper
18 papers, 553 citations indexed

About

Jianling Yang is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Jianling Yang has authored 18 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in Jianling Yang's work include Quinazolinone synthesis and applications (3 papers), Immune cells in cancer (3 papers) and Cancer-related molecular mechanisms research (3 papers). Jianling Yang is often cited by papers focused on Quinazolinone synthesis and applications (3 papers), Immune cells in cancer (3 papers) and Cancer-related molecular mechanisms research (3 papers). Jianling Yang collaborates with scholars based in China and United States. Jianling Yang's co-authors include Lixiang Xue, Cuiqing Ma, Lin Wei, Zhiyan Yao, Ji‐Long Chen, Shile Huang, Zihan Pan, Jing Zhang, Yahong Chen and Jing Fan and has published in prestigious journals such as Cancer Research, Journal of Virology and Biochemical and Biophysical Research Communications.

In The Last Decade

Jianling Yang

17 papers receiving 547 citations

Hit Papers

Hydrogen sulfide alleviates particulate matter-induced em... 2022 2026 2023 2024 2022 40 80 120

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jianling Yang China 12 259 122 112 107 102 18 553
Anouk L. Feitsma Netherlands 13 245 0.9× 101 0.8× 83 0.7× 185 1.7× 59 0.6× 19 840
Chao He China 17 277 1.1× 128 1.0× 104 0.9× 86 0.8× 140 1.4× 58 700
Yang Guo China 16 350 1.4× 105 0.9× 86 0.8× 106 1.0× 83 0.8× 36 666
Jun‐Kai Kao Taiwan 14 207 0.8× 55 0.5× 110 1.0× 166 1.6× 93 0.9× 32 575
Julien Wartelle France 13 155 0.6× 108 0.9× 73 0.7× 191 1.8× 174 1.7× 15 654
Aijun Chen China 15 195 0.8× 93 0.8× 121 1.1× 104 1.0× 41 0.4× 47 702
Yonglie Zhou China 12 198 0.8× 73 0.6× 40 0.4× 104 1.0× 99 1.0× 32 531
Mingqin Lu China 13 195 0.8× 86 0.7× 105 0.9× 98 0.9× 98 1.0× 35 528
Qiaoli Zheng China 12 267 1.0× 117 1.0× 140 1.3× 88 0.8× 42 0.4× 30 627
Shanshan Zhang China 12 311 1.2× 176 1.4× 95 0.8× 302 2.8× 59 0.6× 44 757

Countries citing papers authored by Jianling Yang

Since Specialization
Citations

This map shows the geographic impact of Jianling Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianling Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianling Yang more than expected).

Fields of papers citing papers by Jianling Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianling Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianling Yang. The network helps show where Jianling Yang may publish in the future.

Co-authorship network of co-authors of Jianling Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Jianling Yang. A scholar is included among the top collaborators of Jianling Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianling Yang. Jianling Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Guo, Zhengyang, Yuqing Wang, Jiagui Song, et al.. (2025). Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment. EBioMedicine. 119. 105879–105879.
2.
Guo, Zhengyang, Jiaqi Huang, Xiao Huo, et al.. (2024). Targeting LTA4H facilitates the reshaping of the immune microenvironment mediated by CCL5 and sensitizes ovarian cancer to Cisplatin. Science China Life Sciences. 67(6). 1226–1241. 11 indexed citations
3.
Chang, Chun, Ying Liang, Ting Zhang, et al.. (2024). Elevated CD4+ T Cell Senescence Associates with Impaired Immune Responsiveness in Severe COVID-19. Aging and Disease. 3 indexed citations
4.
Ma, Yun, Guijie Guo, Tingting Li, et al.. (2022). A novel imatinib-upregulated long noncoding RNA plays a critical role in inhibition of tumor growth induced by Abl oncogenes. Molecular Cancer. 21(1). 5–5. 7 indexed citations
5.
Wang, Ying, Zihan Pan, Jing Fan, et al.. (2022). Hydrogen sulfide alleviates particulate matter-induced emphysema and airway inflammation by suppressing ferroptosis. Free Radical Biology and Medicine. 186. 1–16. 132 indexed citations breakdown →
6.
He, Wei, Xuehua Zhu, Ye Yan, et al.. (2021). Ultrasound-mediated microbubbles cavitation enhanced chemotherapy of advanced prostate cancer by increasing the permeability of blood-prostate barrier. Translational Oncology. 14(10). 101177–101177. 25 indexed citations
7.
Huang, Jiaqi, Jie Zhang, Zhengyang Guo, et al.. (2021). Easy or Not—The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity. Frontiers in Immunology. 12. 741302–741302. 19 indexed citations
8.
Yang, Jianling, Zhengyang Guo, Xu Liu, et al.. (2020). Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model. Frontiers in Pharmacology. 11. 574720–574720. 30 indexed citations
9.
Gong, Yueqing, Jianling Yang, Yan Wang, Lixiang Xue, & Junjie Wang. (2020). Metabolic factors contribute to T‐cell inhibition in the ovarian cancer ascites. International Journal of Cancer. 147(7). 1768–1777. 21 indexed citations
10.
Wang, Xuefei, Jianling Yang, Guijie Guo, et al.. (2019). Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway. Molecular Cancer. 18(1). 84–84. 33 indexed citations
11.
Yang, Jianling, et al.. (2019). Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. Xenobiotica. 50(6). 685–688. 4 indexed citations
12.
Li, Miao, Jian Li, Jianling Yang, et al.. (2018). Respiratory Syncytial Virus Replication Is Promoted by Autophagy-Mediated Inhibition of Apoptosis. Journal of Virology. 92(8). 79 indexed citations
13.
Yang, Jing, Zhiqiang Liu, Huan Liu, et al.. (2017). C-reactive protein promotes bone destruction in human myeloma through the CD32–p38 MAPK–Twist axis. Science Signaling. 10(509). 31 indexed citations
14.
Song, Xiaotian, Zhiyan Yao, Jianling Yang, et al.. (2016). HCV core protein binds to gC1qR to induce A20 expression and inhibit cytokine production through MAPKs and NF-κB signaling pathways. Oncotarget. 7(23). 33796–33808. 26 indexed citations
15.
Chen, Ke, Jianling Yang, Jianning Li, et al.. (2016). eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants. Oncotarget. 7(9). 10073–10089. 20 indexed citations
16.
Yang, Jianling, Jun Wang, Ke Chen, et al.. (2013). eIF4B Phosphorylation by Pim Kinases Plays a Critical Role in Cellular Transformation by Abl Oncogenes. Cancer Research. 73(15). 4898–4908. 57 indexed citations
17.
Hu, Jian, et al.. (2012). [Effects of mustard seed on 2, 4-dinitrofluorobenzene-induced allergic contact dermatitis in BALB/c mice].. PubMed. 32(4). 569–72. 3 indexed citations
18.
Yin, Xiaolin, Ying Liu, Jianling Yang, et al.. (2010). Enhancement of the innate immune response of bladder epithelial cells by Astragalus polysaccharides through upregulation of TLR4 expression. Biochemical and Biophysical Research Communications. 397(2). 232–238. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026